Experimental Cell Research, Год журнала: 2025, Номер unknown, С. 114531 - 114531
Опубликована: Март 1, 2025
Язык: Английский
ACS Nano, Год журнала: 2024, Номер 18(14), С. 9784 - 9797
Опубликована: Март 12, 2024
Extracellular vesicles (EVs) secreted by all cell types are involved in the cell-to-cell transfer of regulatory factors that influence and tissue phenotypes normal diseased tissues. EVs thus a rich source biomarker targets for assays analyze blood urinary disease diagnosis. Sensitive detection derived from specific populations is key major hurdle when analyzing complex biological samples, but innovative approaches surveyed this Perspective can streamline EV isolation enhance sensitivity procedures required clinical application EV-based diagnostics therapeutics, including nanotechnology microfluidics, to achieve characterizations. Finally, also outlines opportunities challenges remaining translation assays.
Язык: Английский
Процитировано
29
ACS Nano, Год журнала: 2024, Номер 18(9), С. 6748 - 6765
Опубликована: Фев. 23, 2024
Extracellular vesicles (EVs) are natural lipid nanoparticles secreted by most types of cells. In malignant cancer, EVs derived from cancer cells contribute to its progression and metastasis facilitating tumor growth invasion, interfering with anticancer immunity, establishing premetastasis niches in distant organs. recent years, multiple strategies targeting cancer-derived have been proposed improve patient outcomes, including inhibiting EV generation, disrupting during trafficking, blocking uptake recipient Developments engineering also show promising results harnessing as agents. Here, we summarize the current understanding origin functions review progress therapy these EVs.
Язык: Английский
Процитировано
17
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Янв. 13, 2025
This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple types. As small extracellular vesicles, exosomes exhibit high biocompatibility low immunogenicity, making them ideal vehicles capable of efficiently targeting cells, minimizing off-target damage side effects. aims to explore the potential with a focus on applications chemotherapy, gene immunomodulation. Additionally, challenges related production standardization are analyzed, highlighting importance addressing these issues clinical application. In conclusion, systems offer promising future therapies. Further research should aim enhance efficiency facilitate translation, paving way innovative treatment strategies.
Язык: Английский
Процитировано
10
ACS Pharmacology & Translational Science, Год журнала: 2024, Номер 7(4), С. 967 - 990
Опубликована: Март 19, 2024
Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized effective disease management. Identification key driver mutations molecular profiling have deepened our comprehension genetic alterations in cancer, facilitating targeted therapy immunotherapy selection. Biomarkers such as microsatellite instability (MSI) DNA mismatch repair deficiency (dMMR) guide decisions, opening avenues for immunotherapy. Emerging liquid biopsies, artificial intelligence, machine learning promise to revolutionize early detection, monitoring, selection precision medicine. Despite these advancements, ethical regulatory challenges, including equitable access data privacy, emphasize importance responsible implementation. The dynamic nature with its tumor heterogeneity clonal evolution, underscores necessity adaptive strategies. future lies potential enhance patient care, clinical outcomes, understanding this intricate disease, marked by ongoing evolution field. current reviews focus on providing in-depth knowledge various diverse approaches utilized against at both biochemical levels.
Язык: Английский
Процитировано
15
Pharmaceutics, Год журнала: 2024, Номер 16(6), С. 709 - 709
Опубликована: Май 24, 2024
Of all the numerous nanosized extracellular vesicles released by a cell, endosomal-originated exosomes are increasingly recognized as potential therapeutics, owing to their inherent stability, low immunogenicity, and targeted delivery capabilities. This review critically evaluates transformative of exosome-based modalities across pharmaceutical precision medicine landscapes. Because precise biomolecular cargo delivery, posited ideal candidates in drug enhancing regenerative strategies, advancing diagnostic technologies. Despite significant market growth projections exosome therapy, its utilization is encumbered substantial scientific regulatory challenges. These include lack universally accepted protocols for isolation complexities associated with navigating environment, particularly guidelines set forth U.S. Food Drug Administration (FDA). presents comprehensive overview current research trajectories aimed at addressing these impediments discusses prospective advancements that could substantiate clinical translation exosomal therapies. By providing analysis both capabilities hurdles therapeutic applications, this article aims inform direct future paradigms, thereby fostering integration systems into mainstream practice.
Язык: Английский
Процитировано
14
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Март 12, 2024
Abstract Continued emergence of SARS-CoV-2 variants concern that are capable escaping vaccine-induced immunity highlights the urgency developing new COVID-19 therapeutics. An essential mechanism for infection begins with viral spike protein binding to human ACE2. Consequently, inhibiting this interaction becomes a highly promising therapeutic strategy against COVID-19. Herein, we demonstrate ACE2-expressing lung spheroid cells (LSC)-derived exosomes (LSC-Exo) could function as prophylactic agent bind and neutralize SARS-CoV-2, protecting host infection. Inhalation LSC-Exo facilitates its deposition biodistribution throughout whole in female mouse model. We show blocks vitro vivo by neutralizing virus. treatment protects hamsters from SARS-CoV-2-induced disease reduced loads. Furthermore, intercepts entry multiple variant pseudoviruses mice shows comparable or equal potency wild-type strain, demonstrating may act broad-spectrum protectant existing emerging virus variants.
Язык: Английский
Процитировано
13
Journal of Controlled Release, Год журнала: 2024, Номер 368, С. 24 - 41
Опубликована: Фев. 21, 2024
Язык: Английский
Процитировано
8
Cancers, Год журнала: 2024, Номер 16(8), С. 1482 - 1482
Опубликована: Апрель 12, 2024
RNA interference is a powerful gene-silencing tool with potential clinical applications. However, its therapeutic use challenging because suitable carriers are unavailable. Exosomes stable small endogenous vesicles that can transport functional molecules to target cells, making them ideal interfering (siRNA) carriers. Herein, we elucidated the of patient-derived exosomes as an siRNA carrier for ovarian cancer (OC) treatment. The were extracted from culture medium primary fibroblasts collected omentum patients OC during surgery. MET proto-oncogene, receptor tyrosine kinase (MET) was selected gene silencing, c-Met siRNAs synthesized and loaded into (Met-siExosomes) via electroporation, treatment effect Met-siExosomes assessed in vitro vivo. downregulated protein levels inhibited cell proliferation, migration, invasion. In xenograft experiments using SKOV3-13 ES-2 selectively peritoneally disseminated tumors. Intraperitoneal suppressed downstream targets cells prolonged mouse survival. successfully delivered intraperitoneally As routinely undergo omentectomy abundant be easily omentum, may represent promising treat OC.
Язык: Английский
Процитировано
8
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Июнь 7, 2024
Abstract Critical challenges remain in clinical translation of extracellular vesicle (EV)-based therapeutics due to the absence methods enrich cells with high EV secretion. Current cell sorting are limited surface markers that uncorrelated secretion or therapeutic potential. Here, we utilize a nanovial technology for enrichment millions single based on This approach is applied select mesenchymal stem (MSCs) as improving treatment. The selected MSCs exhibit distinct transcriptional profiles associated biogenesis and vascular regeneration maintain levels after regrowth. In mouse model myocardial infarction, treatment high-secreting improves heart functions compared low-secreting MSCs. These findings highlight importance regenerative therapies suggest selecting could enhance efficacy.
Язык: Английский
Процитировано
8
Neuroglia, Год журнала: 2025, Номер 6(1), С. 3 - 3
Опубликована: Янв. 4, 2025
Background/Objectives: Glioblastoma (GBM), a highly aggressive grade IV astrocytoma, poses major therapeutic challenge due to the resistance of cancer stem cells (CSCs) existing within its cell population conventional therapies. Recently, we reported that RNA interference targeting CSC protection mechanism significantly improved efficacy. However, challenges remain, including limited transfection efficiency in neural and difficulty crossing blood–brain barrier (BBB). Methods: In this study, investigated potential exosome-mediated delivery cargo GBM by engineering exosomes carry green fluorescent protein (GFP) expressing brain-homing peptide (BHP) on their surface, which has high affinity cells. Results: We found BHP-modified doubled GFP efficacy from 20% 40%, outperforming traditional methods like lipofection vitro. vivo, demonstrated an ability cross BBB targeted brain regions following intranasal subcutaneous administration. Conclusions: These results underscore engineered for efficient enhance against tumors suggest novel avenues delivering biomolecules treatment neurological disorders.
Язык: Английский
Процитировано
1